Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00644293 · ClinicalTrials.gov registry record · Phase 3
A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin Sustained Release Versus 3-Day Azithromycin for the Treatment of Strep Throat in Adolescents and Adults
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 598
- Enrollment target
NCT00644293 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 598 participants.
The verdict
NCT00644293, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 598 participants
- Enrollment target
Study Summary
To determine if a single 2.0-g dose of azithromycin SR is at least as effective as a 3-day course of azithromycin (500 mg once daily for 3 days) when used to treat adolescents and adults with strep throat, and to assess efficacy and safety for both treatment regimens.
Interventions
- DRUG placebo
- DRUG azithromycin (Zithromax)
- DRUG azithromycin SR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 598 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00644293
The ClinicalTrials.gov registry entry for NCT00644293 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 598 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00644293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00644293 about?
NCT00644293 is a clinical study titled "A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin Sustained Release Versus 3-Day Azithromycin for the Treatment of Strep Throat in Adolescents and Adults". To determine if a single 2.0-g dose of azithromycin SR is at least as effective as a 3-day course of azithromycin (500 mg once daily for 3 days) when used to treat adolescents and adults with strep throat, and to assess efficacy and safety for both treatment regimens.
What is the current status of trial NCT00644293?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 598 participants. The study started on 2003-01. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00644293?
The interventions under investigation include: placebo (DRUG), azithromycin (Zithromax) (DRUG), azithromycin SR (DRUG).
Who is sponsoring clinical trial NCT00644293?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.